<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300608</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00007024</org_study_id>
    <nct_id>NCT04300608</nct_id>
  </id_info>
  <brief_title>Measures of Mitochondria Dysfunction in PD</brief_title>
  <official_title>Functional and Metabolomic Biomarkers of Mitochondrial Dysfunction in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates metabolic and functional parameters in the skeletal muscle of
      Parkinson's disease patients for comparison to a set of healthy age-matched controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to identify the unique signature of bioenergetic markers and
      mitochondrial (dys)function in muscle of individuals with PD, who are 65-85 of age, read and
      speak English, have a Hoehn &amp; Yahr score between 2 and 3 (bilateral disease, not severely
      disabled) and have a clinical diagnosis of PD. Bioenergetic markers and muscle functional
      properties will be compared to a control dataset collected over the last few years from
      healthy elderly subjects in the same age range to provide a foundation for future
      intervention studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ATPmax</measure>
    <time_frame>baseline</time_frame>
    <description>Maximal mitochondrial ATP production rates measured by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NAD(H) metabolites</measure>
    <time_frame>baseline</time_frame>
    <description>Measurement of relative NAD(H) metabolite concentrations in resting skeletal muscle by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle force and endurance</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum voluntary contraction (MVC) force in Newtons and fatigue resistance assessed by the ability to maintain repeated contractions at 70% MVC will be measured in the hand (flexor digitorum interroseus) and leg (tibialis anterior) using isometric contractions in a custom made apparatus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial metabolites</measure>
    <time_frame>baseline</time_frame>
    <description>Separate measurement of NAD(H) metabolite concentrations in cytosol and mitochondria by magnetic resonance spectroscopy in resting skeletal muscle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between self report function and mitochondrial energetics</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation between self report of fatigue, balance, and muscle pain (PRO-PD) with ATPmax rates and NAD(H) metabolite concentrations measured using magnetic resonance spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between clinical assessment and mitochondrial energetics</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation between UPDRS with ATPmax and NAD(H) metabolites</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease, Mitochondrial</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Parkinson's disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65-85 years.

          -  Ability to attend a 3-hour study visit in Seattle, WA.

          -  Ability to read and speak English.

          -  Hoehn &amp; Yahr Stage 2-3. (bilateral disease, not severely disabled.)

        Exclusion Criteria:

          -  Any contra-indication to magnetic resonance imaging

          -  A history of epilepsy, stroke, brain surgery, or structural brain disease.

          -  The presence of other serious illnesses

          -  Current or recent enrollment in a clinical trial involving an investigational product
             or device.

          -  Supplementation with NAD, nicotinamide mononucleotide (NMN), nicotinamide riboside
             (NR), and other nutraceuticals designed to target NAD for 30 days prior to baseline
             study visit.

          -  Current drug or alcohol use or dependence.

          -  Inability/unwillingness to provide informed consent. (e.g. diagnosis of dementia,
             confusion about study goals or participation.)

          -  Acute infection (e.g. upper respiratory, dermal) in the previous 30 days.

          -  Right limb tremor or dyskinesia that cannot be comfortably controlled for 90 minutes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David Marcinek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurie Mischley, ND, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bastyr University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophia Liu, PhD</last_name>
    <phone>206-685-3533</phone>
    <email>sophia21@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurie Mischley, ND, MPH, PhD</last_name>
    <phone>(206) 525-8012</phone>
    <email>lauriemischley@mac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Liu, PhD</last_name>
      <phone>206-685-3533</phone>
      <email>sophia21@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric Shankland, PhD</last_name>
      <phone>206-685-3533</phone>
      <email>shanklan@uw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>David Marcinek</investigator_full_name>
    <investigator_title>Professor of Radiology Research</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Skeletal Muscle</keyword>
  <keyword>Bioenergetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

